2026 CSCO Annual Meeting takeaways: SCLC, BsAb, ADC are keywords; busy schedule with packed participants

Nomura's China healthcare research note summarizes takeaways from the 29th Chinese Society of Clinical Oncology (CSCO) annual meeting, where SCLC, bispecific antibodies (BsAb) and ADCs stood out as keywords. About 80+ dedicated sessions and roughly 60 satellite sessions were held, with only slightly fewer participants than in 2025, suggesting high-regarded academic meetings still attract physicians. Positive developments on Chinese B7-H3 ADC assets in SCLC were a highlight, with Hansoh's HS-20093 showing promising data in 2L SCLC. Ivonescimab's success is spurring rapid development of other PD-1/VEGF BsAbs or PD-1 combo VEGF agents into phase III trials in 1L NSCLC. ADC updates were another hot topic, featuring Kelun Biotech's sac-TMT and Biokin's iza-bren. Hengrui's and Hansoh's satellite sessions highlighted HER2 ADC and 3rd-generation EGFR TKI roles, respectively. These China-originated therapies have a chance to change treatment practice.